Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Advancing the potential of pep...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Advancing the potential of peptide-PMO compounds in exon skipping therapy for DMD
Bibliographic Details
Main Authors:
Godfrey, C
,
McClorey, G
,
Coursindel, T
,
Betts, C
,
Hammond, S
,
Andaloussi, S
,
Gait, M
,
Wood, M
Format:
Conference item
Published:
2012
Holdings
Description
Similar Items
Staff View
Similar Items
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.
by: Betts, C, et al.
Published: (2012)
Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment
by: Betts, C, et al.
Published: (2018)
Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
by: Blain, A, et al.
Published: (2018)
Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy.
by: Roberts, T, et al.
Published: (2012)
Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient
by: Saito, T, et al.
Published: (2010)